Back to Stocks

ABSI

Absci Corp
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Absci is positioning itself as a disruptor in the biologics space by leveraging an AI-native 'lab-in-the-loop' platform to compress the traditional drug discovery timeline.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The financial reality presented in the latest filing reveals a precarious situation characterized by an accelerating cash burn and a collapse in top-line growth.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ABSI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q paints a picture of a high-stakes technological bet where the valuation is decoupled from current fundamentals and tied entirely to future clinical validation. Absci has successfully built a sophisticated AI engine and a lean pipeline, but it is currently operating as a cash-consuming entity with negligible revenue. The tension for investors lies in whether the platform's efficiency can translate into clinical success before the current cash reserves are exhausted. The company is effectively in a race against time. The upcoming data readouts for ABS-201 in late 2026 are the critical pivot point; positive results would validate the AI-native approach and likely attract the large-scale partnerships needed to stabilize the balance sheet. Conversely, any delay or failure in these trials would leave the company with a dwindling cash pile and a need for highly dilutive financing at a time when market confidence may be eroded. Ultimately, Absci is transitioning from a platform-story to a product-story. While the AMD partnership provides a technical halo, the fundamental risk remains the inherent uncertainty of biologic drug development. The market must now decide if the promised compression of discovery timelines is a sustainable competitive advantage or a speculative narrative masking a traditional biotech burn rate.

Selected Quarter

Core Takeaway

The company is transitioning to a clinical-stage entity with a strong cash position but dangerously low and concentrated revenue.

Investor Lens

The trade-off is between the potential for a platform-wide re-rating upon clinical success versus the risk of a dilutive capital raise before data is released.

Watch Next

Interim proof-of-concept data for ABS-201 in androgenetic alopecia expected in H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.42Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%
bearishMay 7

Partner revenue collapsed by 82% year-over-year to $0.2 million.

earnings miss
90%
bearishMay 7

Net loss increased to $29.6 million as R&D expenses rose 18%.

margin compression
70%
bearishMay 7

Significant outstanding stock options and active ATM program suggest future dilution.

dilution risk
60%
bullishMay 7

Management confirms liquidity is sufficient for at least 12 months of operations.

guidance raise
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The latest 10-Q paints a picture of a high-stakes technological bet where the valuation is decoupled from current fundamentals and tied entirely to future clinical validation. Absci has successfully built a sophisticated AI engine and a lean pipeline, but it is currently operating as a cash-consuming entity with negligible revenue. The tension for investors lies in whether the platform's efficiency can translate into clinical success before the current cash reserves are exhausted. The company is effectively in a race against time. The upcoming data readouts for ABS-201 in late 2026 are the critical pivot point; positive results would validate the AI-native approach and likely attract the large-scale partnerships needed to stabilize the balance sheet. Conversely, any delay or failure in these trials would leave the company with a dwindling cash pile and a need for highly dilutive financing at a time when market confidence may be eroded. Ultimately, Absci is transitioning from a platform-story to a product-story. While the AMD partnership provides a technical halo, the fundamental risk remains the inherent uncertainty of biologic drug development. The market must now decide if the promised compression of discovery timelines is a sustainable competitive advantage or a speculative narrative masking a traditional biotech burn rate.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.